drugset / Trial / NCT01077375
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-12
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Milnacipran | Other / unclassified | 100 mg | Oral |
| Subject | Milnacipran | Other / unclassified | 200 mg | Oral |
| Comparator | Duloxetine | Small molecule | 30 mg | Oral |